GHRSNasdaqPharmaceutical PreparationsUS GAAP · USD

GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company focused on developing mebufotenin-based therapies for treatment-resistant depression. The company is organized through its Irish holding company and wholly owned Irish subsidiary, with its pipeline centered on GH001, an inhalable product candidate, and GH002, an intravenous product candidate.

Kysy yhtiöstä

Liiketoiminta

Osuus liikevaihdosta
GH00150 %

Inhalable mebufotenin product candidate being developed for TRD.

GH00230 %

Intravenous mebufotenin product candidate being developed for TRD.

Clinical development services20 %

Internal research, clinical operations, and regulatory development work.

Asiakkaat

GH Research does not sell commercial drugs today; its direct economic stakeholders are patients, physicians, clinical investigators, regulators, and prospective commercialization partners. The intended end users are adults with treatment-resistant depression, while the immediate buyers in any future commercial model would likely be hospitals, clinics, payers, and specialty prescribers. Current activity is centered on clinical trial participants and the medical centers that conduct and support studies.

Patients with treatment-resistant depression

The core therapeutic population targeted by GH001 and GH002 for eventual treatment use.

Psychiatrists and specialty clinics

Physicians and treatment centers that would administer or prescribe the therapy if approved.

Clinical trial sites

Hospitals, research centers, and investigators that enroll patients and generate clinical data.

Regulators and ethics committees

They review safety, efficacy, and trial design before later-stage development and approval.

Future commercial payers

Insurers and health systems that would influence access and reimbursement after approval.

Strategia

GH Research’s strategy is to advance mebufotenin-based therapies through clinical development, with GH001 as the central program and GH002 as a follow-on candidate. The company’s direction depends on generating clinical evidence, aligning trial design with regulators, and preserving capital to fund development through key milestones.

Advance GH001 clinical programLyhyt aikaväli

GH001 is the lead asset and the main path to proof of concept and eventual approval.

Develop GH002Keskipitkä aikaväli

A second product candidate broadens the platform and provides an additional development path.

Maintain development fundingLyhyt aikaväli

Clinical programs require sustained capital to support trials, regulatory work, and operations.

Maantiede

The company is incorporated in Ireland and has its registered office in Dublin, while its securities are listed in the United States on Nasdaq. Its current development work is international in nature because clinical biopharmaceutical programs typically require trial sites, regulators, and service providers across multiple jurisdictions. The available reports do not disclose country-by-country revenue, consistent with a pre-commercial development stage.

Riskit

The main risks are clinical and regulatory: the company may fail to demonstrate efficacy and safety, may not secure favorable FDA alignment, or may face trial delays and clinical hold risk. As a clinical-stage biopharmaceutical company, GH Research also depends on external financing and is exposed to valuation, dilution, and execution risk before any commercial revenue exists.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Clinical development failure1Regulatory misalignment3Clinical hold risk4Financing and dilution2
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen

    Drug candidates may not demonstrate acceptable efficacy, safety, or tolerability in trials.

    Kohdistuu: GH001 and GH002

  2. Financing and dilutionVaikutus: KorkeaTodennäköisyys: Korkea

    As a pre-revenue biotech, the company relies on equity capital to fund operations.

    Kohdistuu: Public offerings and investor capital

  3. Regulatory misalignmentVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company needs regulatory agreement on pivotal design and development plans.

    Kohdistuu: FDA alignment on Phase 3 program

  4. Clinical hold riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Future trials can be delayed or halted by regulators if safety or protocol issues arise.

    Kohdistuu: GH001 and GH002 trials

Kysy Clarifolta: GH Research PLC

Kirjanpito

Harkinnanvaraiset erät
Fair value of marketable securities

Quoted instruments are measured at fair value and affect liquidity presentation and gains/losses.

Vaikutus: Changes can affect cash-like resources and reported results.

Share-based compensation

Employee and director awards are recognized over vesting periods and can be material for a biotech.

Vaikutus: Raises operating expense without cash outflow.

Lease accounting

Lease liability payments are shown in financing cash flows and affect cash flow presentation.

Vaikutus: Important for understanding operating versus financing cash usage.

Clinical trial expense timing

Development costs are recognized as incurred, so trial timing affects quarterly comparability.

Vaikutus: Can cause volatility in research and development expense.

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

Biohaven Ltd.

BHVN · Pharmaceutical Preparations

Prothena Corporation plc

PRTA · Pharmaceutical Preparations

Atai Beckley N.V.

Pharmaceutical Preparations

Pasithea Therapeutics Corp.

KTTA · Pharmaceutical Preparations

Celcuity Inc.

CELC · Services-Medical Laboratories

Päivitetty: 28.9.2026